Protagonist Therapeutics – $90 Million IPO

Palo Alto – August 29, 2016 – Cooley advised Protagonist Therapeutics on its $90 million initial public offering. The company now trades on The NASDAQ Global Market under the symbol "PTGX."

Protagonist is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs.

The Cooley corporate and securities team advising Protagonist included Mike Tenta, Kenn Guernsey, Glen Sato, Josh Seidenfeld, Pete Mandel, Jared Verzello and Mei Li.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Michael Tenta  Partner Palo Alto
Kenneth Guernsey  Partner San Francisco, Palo Alto
Lesse Castleberry  Senior Counsel New York
Carol Laherty  Partner Seattle
Natasha Leskovsek  Of Counsel Washington, DC
Barbara Mirza  Partner Los Angeles, Palo Alto
Francis Wheeler  Partner Colorado
Mark Windfeld-Hansen  Senior Counsel Palo Alto
Nancy Wojtas  Senior Counsel Palo Alto
Josh Seidenfeld  Partner Palo Alto